<DOC>
	<DOCNO>NCT01178788</DOCNO>
	<brief_summary>Objective : This trial would evaluate clinical effectiveness Progesterone ( P ) 17-hydroxy Progesterone ( 17P ) reduce PTD , symptomatic woman risk cervical shortening , present pregnancy . Main outcome : Delivery 37 week . Secondary outcome : Gestational age delivery , Delivery &lt; 32 , &lt; 35 wks , hospital admission delivery , birth-weight centile , NICU admission , day NICU admission , day oxygen supply , composite neonatal complication , congenital neonatal malformation anomaly . Allocated treatment : Group A : 17P 341 mg i.m./weekly ( Lentogest , AMSA , Italy ) ; Group B : micronized P 200 mg per vagina /day ( Utrogestan , Besins Healthcare , Belgium ) Group C : treatment , clinical observation Concomitant treatment : Iron folic acid supplementation , Betamethasone ( 12 mg repeat 24 hour apart ) permit . Is allow treatment tocolytics per o . Any treatment record . Duration : The period enrollment 15 month . Cases randomize clinical unit competitively assign later . Results expect 20-24 month start . Sample Size : hypothesizing risk PTD = 0.30 efficacy define reduction 50 % ( risk = 0.15 ) . With test potency = 0.80 alpha = 0.025 study need enrol 160 patients/arm , total 480 patient . Data analysis : Methodological Unit assign randomize treatment web site collect data way .</brief_summary>
	<brief_title>Progestagens Tertiary Prophylaxis Preterm Delivery</brief_title>
	<detailed_description>Background : According last review Progesterone ( P ) ( 17P ) able reduce preterm delivery ( PTD ) , either prophylactic administration presence previous PTD treatment actual pregnancy , become risk cervical shortening/preterm labour . At present difficult distinguish clinical effect P one 17P well impossible choice among diverse dos formulation utilized RCTs publish far , well recruitment . Protocol : Women treat P , 17P clinically observed accord on-line randomization assignment provide Methodological Unit . Treatments end completion 36th week . Randomization stratify early ( 22-27+6th ) late ( 28-31+6th wks ) PTD risk . Interim analysis do 50 % enrollment . Sixty woman allocate Clinical Centre reach 480 enrollment , 3 arm . Drugs provide manufacturer .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>17-alpha-hydroxy-progesterone caproate</mesh_term>
	<mesh_term>11-hydroxyprogesterone</mesh_term>
	<criteria>Women singleton pregnancy 22+0nd 31+6nd week gestation present cervical length â‰¤25 mm , episode preterm labour . Women previous spontaneous PTD , multiple pregnancy , rupture membrane , fetomaternal condition indicate delivery , mullerian malformation , cervical surgery ( cervical cerclage etc ) , presence regular uterine contraction</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Progestagens</keyword>
	<keyword>Tertiary Prophylaxis</keyword>
	<keyword>Micronized Progesterone</keyword>
	<keyword>17 alpha hydroxy P</keyword>
	<keyword>Preterm Delivery</keyword>
	<keyword>Cervical shortening</keyword>
</DOC>